Keyphrases
Radiation Therapy
100%
Phase II Trial
100%
Gastrointestinal Malignancies
100%
Avelumab
100%
Utomilumab
100%
Diarrhea
50%
Treatment-related Adverse Events
50%
Colitis
50%
Immune-related
50%
Solid Tumors
25%
Am(III)
25%
Progressive Disease
25%
Response Rate
25%
Fever
25%
Median Overall Survival
25%
Overall Survival
25%
Tolerability
25%
Radiation Effects
25%
Colon
25%
Stable Disease
25%
Progression-free Survival
25%
Antigen Presentation
25%
Cell Function
25%
Dose-limiting Toxicity
25%
Costimulatory Molecules
25%
Single Institution
25%
Subgroup Analysis
25%
Synergize
25%
Tumor Survival
25%
Safety Concerns
25%
Median Progression-free Survival
25%
Gastrointestinal Tumours
25%
Phase 1/2 Clinical Trial
25%
Multi-arm
25%
Clinical Progression
25%
Advanced Solid Tumors
25%
PD-1 Blockade
25%
Abscopal Effect
25%
OX40 Agonist
25%
Anti-PD-L1 Antibody
25%
4-1BB Agonists
25%
Immune-related Response Criteria
25%
Medicine and Dentistry
Cancer
100%
Radiation Therapy
100%
Avelumab
100%
Utomilumab
100%
Solid Malignant Neoplasm
50%
Adverse Event
50%
Overall Survival
50%
Diarrhea
50%
Colitis
50%
Progression Free Survival
50%
Programmed Death-Ligand 1
50%
Diseases
25%
Clinical Trial
25%
Cell Function
25%
Arm
25%
Progressive Disease
25%
Colon
25%
Antigen Presentation
25%
Subgroup Analysis
25%
Gastrointestinal Tumor
25%
Chill
25%
Abscopal Effect
25%